Clinical Trials Arena on MSN
Inflammasome sets sights on phase III amid eye disease drug’s mid-stage score
K8 slowed disease progression and trended towards improving visual acuity, which Inflammasome says warrants the drug’s ...
After a single intravitreal dose of 4D-150, visual acuity and anatomic control was maintained with consistent and durable treatment burden reduction through 2 years 4D-150 continues to be well tolerat ...
View-tolerant identity recognition in humans depends on the stable identity cues provided by horizontal facial information.
Morning Overview on MSN
By age 70, one in five Americans lives with both vision and hearing loss
Roughly one in five Americans aged 70 and older is living with both hearing loss and vision loss at the same time, according ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果